Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Rashmi KumarDirector | Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 06/08 | 06/09 | 15,000 sh | $4.46 | $66,900 | −8.0% |
Paul BisaroDirector | Myriad GeneticsMYGN | Open-market buy | 05/14 | 05/14 | 7,500 sh | $3.69 | $27,675 | +8.3% |
Samraat S. RahaPresident and CEO | Myriad GeneticsMYGN | Open-market buy | 03/09 | 03/09 | 40,000 sh | $5.00 | $200,000 | +8.8% |
Myriad GeneticsMYGN | Open-market buy | 02/25–02/27 | 02/27 | 104,507 sh3 trades | $4.73avg. | $494,547.6 | +58.9% | |
Paul J. DiazPresident and CEO | Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 24/10/11 | 24/10/11 | 15,000 sh | $22.93 | $343,950 | −1.5% |
Paul J. DiazPresident and CEO | Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 24/09/11 | 24/09/12 | 15,000 sh | $26.72 | $400,800 | −1.5% |
Dale MuzzeyChief Scientific Officer | Myriad GeneticsMYGN | Open-market sale | 24/09/11 | 24/09/12 | 2,100 sh | $26.17 | $54,957 | −1.9% |
Heinrich DreismannDirector | Myriad GeneticsMYGN | Open-market sale | 24/09/09 | 24/09/09 | 10,000 sh | $27.05 | $270,500 | −7.6% |
Colleen F. ReitanDirector | Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 24/09/03 | 24/09/04 | 46,012 sh | $27.95 | $1,286,035.4 | −52.0% |
Margaret AnconaSVP, Chief of Staff | Myriad GeneticsMYGN | Open-market sale | 24/08/21 | 24/08/23 | 11,538 sh | $27.82 | $320,987.16 | −12.7% |
Rashmi KumarDirector | Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 24/08/19 | 24/08/20 | 7,500 sh | $28.01 | $210,075 | −8.8% |
Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 24/06/03–24/06/04 | 24/06/04 | 7,576 sh2 trades | $22.04avg. | $167,012.92 | −18.7% | |
Myriad GeneticsMYGN | Open-market sale | 24/05/13–24/05/15 | 24/05/15 | 227,844 sh3 trades | $25.14avg. | $5,728,819.72 | −17.6% | |
Lee Nisley NewcomerDirector | Myriad GeneticsMYGN | Open-market sale | 24/05/13 | 24/05/15 | 6,200 sh | $25.30 | $156,860 | −8.5% |
Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 23/12/01 | 23/12/05 | 30,000 sh | $19.09 | $572,700 | −9.3% | |
Myriad GeneticsMYGN | Open-market sale10b5-1 plan | 23/11/01 | 23/11/03 | 30,000 sh | $15.69 | $470,700 | −8.5% | |
Daniel K. SpiegelmanDirector | Myriad GeneticsMYGN | Open-market sale | 23/06/02 | 23/06/02 | 8,638 sh | $23.01 | $198,760.38 | −17.6% |
Myriad GeneticsMYGN | Open-market sale | 23/03/27 | 23/03/28 | 6,433 sh | $23.48 | $151,046.84 | −2.6% | |
Myriad GeneticsMYGN | Open-market sale | 23/03/02 | 23/03/03 | 15,000 sh | $22.55 | $338,250 | −4.3% | |
Myriad GeneticsMYGN | Open-market sale | 23/03/02 | 23/03/03 | 13,184 sh | $22.74 | $299,804.16 | −5.8% |